Clinical Trial Update: Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag) [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing Selexipag 400 mcg tablets to Uptravi 400 mcg tablets for pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Selexipag (selexipag)
• Uptravi (selexipag)

Snippet

Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Pulmonary Arterial Hypertension (PAH) | Phase 1 | Status: COMPLETED